ARTICLE | Company News

Biocon, Pfizer sales and marketing update

October 25, 2010 7:00 AM UTC

Biocon partnered with Pfizer to market Biocon's biosimilar versions of insulin and insulin analog products, including recombinant human insulin, glargine, aspart and lispro. The companies will share co-exclusive rights in Germany, India and Malaysia, while Pfizer will have exclusive rights elsewhere, except in a number of developing markets, where Pfizer also will share co-exclusive rights with existing Biocon partners. Biocon remains responsible for clinical development, regulatory activities and manufacturing and supply of the biosimilars. Pfizer said the deal is in line with its strategy to strengthen its presence in follow-on biologics, as well as diabetes. ...